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The ubiquitin-editing protein A20 limits the duration of
NF-kB activation and is essential to control inﬂammatory
responses. Recent experiments have established that A20
mediates its inhibitory function in a complex with two
other proteins, TAX1BP1 and the E3 ligase Itch. In a paper
published in this issue, it is shown that RNF11 is also a
critical component of the A20 ubiquitin-editing complex.
NF-kB transcription factors regulate the expression of numerous
genes involved in inﬂammation and immunity (Li and Verma,
2002). Activation of NF-kB is normally transient, and persistent
NF-kB activation is associated with several autoimmune diseases
and cancer. The duration of NF-kB activation is controlled by a
number of inhibitory proteins, including A20, which functions in a
negative feedback loop to limit NF-kB activation. A20 is essential
Figure 1 Regulation of TNFR1 signalling by ubiquitination. (A) TNF stimulation induces binding of a TRADD–RIP1–TRAF2–TRAF5 complex
to TNFR1. The TRAF proteins then catalyse the K63-linked polyubiquitination of RIP1, inducing RIP1 association with the IKK complex (IKK1/
IKK2/NEMO), which is subsequently activated by a process that involves both its K63-linked ubiquitination and phosphorylation. IKK
phosphorylates IkBa, triggering K48-linked polyubiquitination of IkBa, which induces its subsequent degradation by the proteasome. As a
result, associated NF-kB dimers are freed to translocate into the nucleus and activate the transcription of NF-kB target genes, including A20. (B)
The A20 ubiquitin-editing complex is critical to ensure that NF-kB activation induced by TNF is transient. This complex, comprising A20,
TAX1BP1, Itch and RNF11, catalyses the removal of K63-linked ubiquitin chains from RIP1, utilizing the deubiquitinating activity of A20.
Subsequently, A20 and Itch catalyse addition of K48-linked ubiquitin chains of RIP1, promoting its degradation by the proteasome and
termination of NF-kB activation. K63-linked ubiquitin chains, purple; K48-linked ubiquitin chains, turquoise; P, phosphorylation; Ub,
ubiquitin; þUb, ubiquitination;  Ub, deubiquitination.
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 /  (Tnfaip3
 / ) mice die pre-
maturely from multi-organ inﬂammation caused by deregulated
Toll-like receptor (TLR) signalling in response to commensal in-
testinal bacteria (Lee et al, 2000; Turer et al, 2008). Signiﬁcantly,
A20 has been identiﬁed as a disease-associated gene in rheumatoid
arthritis, systemic lupus erythomatosus, Crohn’s disease and cor-
onary artery disease (Coornaert et al, 2008).
A20 is a deubiquitinating enzyme of the ovarian tumour (OTU)
family and downregulates NF-kB activation by removing K63-linked
ubiquitin chains from key target proteins (Coornaert et al, 2008).
K63-linked ubiquitination, mediated by the tumor necrosis factor
(TNF) receptor-associated factor (TRAF) protein family of E3
ligases, regulates interactions between signalling proteins required
for receptor activation of inhibitor of kB( I kB) kinase (IKK). This
kinase complex triggers IkB proteolysis, releasing NF-kB dimers to
translocate into the nucleus and induce transcription of target
genes, including A20 (Figure 1). A20 inhibition of TNF receptor 1
(TNFR1) signalling to NF-kB involves its removal of K63-linked
ubiquitin chains from receptor-interacting protein (RIP) 1, an
essential adaptor for NF-kB activation by TNFR1. A20 removal of
K63-linked ubiquitin from TRAF6 and RIP2, similarly turns off
activation of NF-kB by TLR4 and nucleotide-binding oligomeriza-
tion domain containing-2 (NOD2), respectively.
Negative regulation of NF-kB signalling by A20 requires two
other proteins with which it associates, Tax1-binding protein 1
(TAX1BP1) and Itch (Heissmeyer and Rao, 2008). TAX1BP1 (also
known as T6BP and TXBP151) functions as an adaptor protein
recruiting A20 to its substrates, K63-ubiquitinated RIP1 and TRAF6,
through a novel ubiquitin-binding domain (Shembade et al, 2007;
Iha et al, 2008). TAX1BP1 also binds to the WW domain of HECT
(homologous to E6-AP carboxyl terminus) domain E3 ligase Itch
through its two conserved PPXY motifs (Pro-Pro-X-Tyr, where X is
any amino acid), recruiting Itch to A20 in TNF-stimulated ﬁbro-
blasts (Shembade et al, 2008). Both TAX1BP1 and Itch are required
for the association of RIP1 with A20, the deubiquitination of RIP1
and TRAF6 by A20, and termination of NF-kB and Jun N-terminal
kinase (JNK) activation after TNF stimulation of ﬁbroblasts.
TAX1BP1 and Itch, therefore, facilitate the targeting and deubiqui-
tination of substrates by A20.
Removal of K63-linked ubiquitin chains by A20 is not sufﬁcient
to turn off the signalling activity of RIP1. This requires RIP1
degradation by the proteasome, induced by its K48-linked
ubiquitination following prolonged TNF stimulation. K48-linked
ubiquitination of RIP1 is mediated by A20, functioning as a
‘ubiquitin-editing’ E3 ligase, and Itch. The K48-linked ubiquitin
E3 ligase activities of both A20 and Itch are required to down-
regulate NF-kB activation by TNF. However it is not known why
two K48-ubiquitin E3 ligases are needed to regulate RIP1 proteo-
lysis, or whether K48-linked ubiquitination of TRAF6 and RIP2 is
also required for A20 to block their activation of NF-kB.
The present study by Harhaj and colleagues shows that ring
ﬁnger protein 11 (RNF11), which may also function as an E3 ligase,
is another essential component of the A20 ubiquitin-editing com-
plex (Shembade et al, 2009). RNF11 was identiﬁed as a gene
overexpressed in breast cancer and has been implicated in tumour
growth factor beta signalling (Azmi and Seth, 2005). The potential
link with A20 was suggested in an earlier two-hybrid screen, which
identiﬁed A20, TAX1BP1 and Itch as potential RNF11-binding
partners (Colland et al, 2004). Shembade et al now show that
endogenous RNF11 interacts with A20, TAX1BP1 and RIP1 in a
TNF-dependent manner in 293T cells and primary murine macro-
phages. They also demonstrate that TNF-induced NF-kB and JNK
activation in human THP-1 monocytes is prolonged after RNF11
knockdown, due to increased RIP1 and TRAF6 polyubiquitination.
Furthermore, immunoprecipitation experiments indicate that RNF11
is required for A20 association with RIP1 after TNF stimulation. A
PPXY motif of RNF11 is needed both to terminate NF-kB signalling
and for complexing with A20, TAX1BP1 and RIP1. The PPXY motif
could bind directly to the Itch WW domain, and one of the functions
of RNF11 may be to facilitate Itch ubiquitination of speciﬁc target
proteins, such as RIP1.
Earlier studies have clearly highlighted the role of associated
proteins in mediating A20’s inhibitory function in NF-kB signalling
in ﬁbroblasts (Shembade et al, 2007, 2008; Iha et al, 2008). Together
with the present work from the Harhaj laboratory (Shembade et al,
2009), these genetic and immunoprecipitation experiments suggest
that negative regulation of NF-kB is mediated by a quaternary A20–
TAX1BP1–Itch–RNF11 complex. However, the role of TAX1BP1 in
mediating A20’s inhibitory function may be restricted to certain
tissues, as Tax1bp1
 /  mice develop inﬂammatory cardiac valvuli-
tis (Iha et al, 2008), whereas inﬂammation is widespread in A20-
deﬁcient mice (Lee et al, 2000). Clearly, the generation and analysis
of Rnf11
 /  mice will be essential to determine the physiological
roles of RNF11 in inﬂammatory responses, and whether RNF11
regulation of A20 function is tissue or stimulus speciﬁc. Such
analyses will help to establish whether RNF11 is the last piece in
the A20 ubiquitin-editing complex puzzle, or whether more remain
to be discovered.
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